Table 1.
Baseline characteristics of the included patients in the TCGA database.
| Characteristic | Total | MOR (-) | MOR (+) |
|---|---|---|---|
| N = 7274 | N = 6162 | N = 1112 | |
| Age | 59.0 ± 14.2 | 59.3 ± 14.0 | 57.4 ± 15.2 |
| Age group | |||
| Young | 3630 | 3059 (49.6) | 571 (51.3) |
| Old | 3542 | 3024 (49.1) | 518 (46.6) |
| Gender | |||
| Female | 3604 | 3114 (50.5) | 490 (44.1) |
| Male | 3612 | 3003 (48.7) | 609 (54.8) |
| Race | |||
| Caucasian | 5222 | 4376 (71.0) | 846 (76.1) |
| African | 686 | 581 (9.4) | 105 (9.4) |
| AJCC stage | |||
| Stage I | 1755 | 1556 (25.3) | 199 (17.9) |
| Stage II | 1710 | 1492 (24.2) | 218 (19.6) |
| Stage III | 1281 | 1146 (18.6) | 135 (12.1) |
| Stage IV | 689 | 571 (9.3) | 118 (10.6) |
| Grade | |||
| Low Grade | 1392 | 1073 (17.4) | 319 (28.7) |
| High Grade | 1490 | 1158 (18.8) | 332 (29.9) |
| AJCC-T | |||
| T1 | 1556 | 1404 (22.8) | 152 (13.7) |
| T2 | 2205 | 1921 (31.2) | 284 (25.5) |
| T3 | 1817 | 1599 (25.9) | 218 (19.6) |
| T4 | 554 | 463 (7.5) | 91 (8.2) |
| AJCC-N | |||
| N0 | 3247 | 2860 (46.4) | 387 (34.8) |
| N1 | 1380 | 1203 (19.5) | 177 (15.9) |
| N2 | 589 | 497 (8.1) | 92 (8.3) |
| N3 | 154 | 144 (2.3) | 10 (0.9) |
| AJCC-M | |||
| M0 | 3872 | 3435 (55.7) | 437 (39.3) |
| M1 | 251 | 208 (3.4) | 43 (3.9) |
MOR (+) represented positive MOR mRNA expression; MOR (-) represented negative MOR mRNA expression; Young, under 60 years old; Old, over 60 years old; All the variables were described as frequencies and percentages, except for age described as mean and standard deviation.
TCGA, the Cancer Genome Atlas; MOR, mu opioid receptor; AJCC, the American Joint Committee on Cancer; TNM, Tumor node metastasis.